Company performance
Current Price
as of Jan 17, 2025$1.80
P/E Ratio
N/A
Market Cap
$2.88M
- PVT
Description
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.
Metrics
Overview
- HQHouston, TX
- SectorHealth Technology
- IndustryBiotechnology
- TickerTCRT
- Price$1.8+4.05%
Trading Information
- Market cap$2.88M
- Float86.25%
- Average Daily Volume (1m)26,815
- Average Daily Volume (3m)24,810
- EPS-$7.36
Company
- Revenue$0.01M
- Rev growth (1yr)N/A
- Net income-$1.13M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$1.15M
- EV$3.47M
- EV/Revenue578.84
- P/EN/A
- P/S480.38
- P/B1.06
Documents
SEC Filings